The Business of Clinical Trials Is Booming. Private Equity Has Taken Notice.
Private equity firms have moved aggressively into the healthcare industry’s more hidden niches: They are pouring billions into the business of clinical drug trials.
Stay updated with breaking news from Cecil Nick. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Private equity firms have moved aggressively into the healthcare industry’s more hidden niches: They are pouring billions into the business of clinical drug trials.
After finding success investing in the more obviously lucrative corners of American medicine — like surgery centers and dermatology practices — private equity firms have moved aggressively into the industry’s more hidden niches: They are pouring billions into the business of clinical drug trials. To bring a new drug to market, the FDA requires pharmaceutical
After finding success investing in the more obviously lucrative corners of American medicine — like surgery centers and dermatology practices — private equity firms have moved aggressively into the industry's more hidden niches: They are pouring billions into the business of clinical drug trials.
April 22, 2021 published at 12:30 PMglobenewswire Dyadic International Hosting a Fireside Chat on “The Potential of the Transformative Dyadic C1 Protein Technology in Helping Meet Global Health Challenges” Fireside Chat Being Held on Tuesday, May 4th @ 10am Eastern Time GlobeNewswire April 22, 2021 JUPITER, Fla., April 22, 2021 (GLOBE NEWSWIRE) -- Dyadic International, Inc. ("Dyadic", "we", "us", "our", or the "Company") (NASDAQ:DYAI), a global biotechnology company focused on developing and deploying its proprietary C1-cell protein production platform to optimize the development of v...
Share: JUPITER, Fla., April 22, 2021 (GLOBE NEWSWIRE) -- Dyadic International, Inc. ("Dyadic", "we", "us", "our", or the "Company") (NASDAQ:DYAI), a global biotechnology company focused on developing and deploying its proprietary C1-cell protein production platform to optimize the development of vaccines, therapeutics and other protein based products today announced that it will host a fireside chat on Tuesday, May 4, 2021 at 10:00am Eastern Time. The fireside chat will focus on the potential of the transformative Dyadic C1 protein technology in helping meet global health challenges. The mo...